Management of atrial fibrillation in patients with structural heart disease

Circulation

Volumn 125, Issue 7, 2012, Pages 945-957

  Darby, Andrew E ^a   DiMarco, John P ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Atrial fibrillation; Atrial fibrillation arrhythmia; Atrial fibrillation heart failure; Congenital heart disease; Hypertrophic cardiomyopathy

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DABIGATRAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; DOFETILIDE; DRONEDARONE; EDOXABAN; FLECAINIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE GAMMA 2; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; PLACEBO; RIVAROXABAN; SOTALOL; UNCLASSIFIED DRUG; WARFARIN;

ABLATION THERAPY; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLEEDING; BRUGADA SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CARDIOVERSION; CATHETER ABLATION; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; DEFIBRILLATION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; EBSTEIN ANOMALY; FALLOT TETRALOGY; GASTROINTESTINAL HEMORRHAGE; GREAT VESSELS TRANSPOSITION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ATRIUM SEPTUM DEFECT; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART SINGLE VENTRICLE; HEART VENTRICLE FUNCTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; LOW DRUG DOSE; MITRAL VALVE REGURGITATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SHORT QT SYNDROME; SINUS RHYTHM; STROKE; STRUCTURAL HEART DISEASE; TACHYCARDIA INDUCED CARDIOMYOPATHY; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TORSADE DES POINTES; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

ATRIAL FIBRILLATION; CARDIOMYOPATHY, HYPERTROPHIC; HEART DEFECTS, CONGENITAL; HEART FAILURE; HEART RATE; HEART VALVE DISEASES; HUMANS; LONG QT SYNDROME; STROKE;

EID: 84857574968     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.019935     Document Type: Article

References (100)

1. Fuster V, Ryden LE, Cannom DS, Crijins HJ, Curtis AB, Ellenbogen KA, Halpern JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114: e257-e354. (Pubitemid 44252297)
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang T.S.M. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000 and implications on the projections for future prevalence. Circulation. 2006;114: 119-125. (Pubitemid 44420743)
3. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell WB, Havranek E, Murray K, Olshansky B, O'Neill G, Sami M, Schmidt S, Storm R, Zabalgoitia M, Miller J, Chandler M, Nasco EM, Greene HL; and the AFFIRM Investigators. Analysis of causespecific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109: 1973-1980. (Pubitemid 38552376)
4. DiMarco JP. Atrial fibrillation and acute decompensated HF. Circ Heart Fail. 2009;2:72-73.
5. Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TSM. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community based study. J Am Coll Cardiol. 2007;49:986-992.
6. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Seward JB, Tsang TSM. Changing trends of hospital utilization in patients after their first episode of atrial fibrillation. Am J Cardiol. 2008;102:568-572.
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2863-2870.
8. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijins HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. CHEST. 2010;137:263-272.
9. Braunwald E. Shattuck lecture: cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360-1369. (Pubitemid 27467771)
10. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-1022. (Pubitemid 12155370)
11. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271:840-844.
12. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003; 91:2D-8D. (Pubitemid 36369329)
13. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002;13: 399-405. (Pubitemid 34407608)
14. Seiler J, Stevenson WG. Atrial fibrillation in congestive heart failure. Cardiol Rev. 2010;8:38-50.
15. Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet. 2003;362:147-158. (Pubitemid 36831029)
16. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-216. (Pubitemid 40348525)
17. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials: Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695-703. (Pubitemid 28435256)
18. Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pederson C, Poole-Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. Eur Heart J. 2005;26: 1303-1308. (Pubitemid 41435461)
19. Pederson OD, Bagger H, Kóber L, Torp-Pederson C; for the TRACE Study Group. Impact of congestive heart failure and left ventricular systolic function on the prognostic significance of atrial fibrillation and atrial flutter following acute myocardial infarction. Int J Cardiol. 2005;100:65-71. (Pubitemid 40487938)
20. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJV, Puu M, Yusuf S, Pfeffer MA. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. J Am Coll Cardiol. 2006;47:1997-2004.
21. Ahmed A, Perry GJ. Incident atrial fibrillation and mortality in older adults with heart failure. Eur J Heart Fail. 2005;7:1118-1121. (Pubitemid 41721113)
22. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;69:1570-1573.
23. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29: 709-715. 24. (Pubitemid 27128241)
24. Khasnis A, Jongnarangsin K, Abela G, Veerareddy S, Reddy V, Thakur R. Tachycardia-induced cardiomyopathy: a review of literature. Pacing Clin Electrophysiol. 2005;28:710-721. (Pubitemid 41001445)
25. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;119: e391-e479.
26. Kanji S, Stewart R, Fergusson DA, McIntyre L, Turgeon AF, Hebert PC. Treatment of new onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials. Crit Care Med. 2008;36:1620-1624. (Pubitemid 351620656)
27. Schirmer SH, Baumhakel M, Neuberger H-R, Hohnloser SH, van Gelder IC, Lip GYH, Bohm M. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol. 2010;56:2067-2076.
28. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
29. Camm AJ, Kirchof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohnloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation. Europace. 2010;12:1360-1420.
30. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershville J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PHJM, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283:1295-1302. (Pubitemid 30129796)
31. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies-CIBIS and CIBIS II. Am Heart J. 2002;143: 301-307.
32. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation. 2002;106:2194-2199. (Pubitemid 35222212)
33. Joglar JA, Acusta AP, Shusterman NH, Ramaswamy K, Kowal RC, Barbera SJ, Hamdan MH, Page RL. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular systolic dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J. 2001;142:498-501. (Pubitemid 32801635)
34. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation. 1998;98: 2574-2579. (Pubitemid 29001197)
35. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363-1373.
36. Farshi R, Kistner D, Sarma JSM, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304-310. (Pubitemid 29234189)
37. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: ameta-analysis. Circulation. 2000;101:1138-1144. (Pubitemid 30146615)
38. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH, Pires LA. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005;16: 1160-1165.
39. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; for the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833. (Pubitemid 35417773)
40. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; for the Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840. (Pubitemid 35417774)
41. Freudenberger RS, Wilson AC, Kostis JB; AFFIRM Investigators and Committees. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol. 2007;100:247-252. (Pubitemid 47042000)
42. Pederson OD, Brendorp B, Elming H, Pehrson H, Kober L, Torp-Pedersen C. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. Card Electrophysiol Rev. 2003;7:220-224. (Pubitemid 38256102)
43. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BH, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; for the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358:2667-2677. (Pubitemid 351860859)
44. Talajic M, Khairy P, Levesque S, Connolly SJ, Dorian P, Dubuc M, Guerra PG, Hohnloser SH, Lee KL, Macle L, Nattel S, Pedersen OD, Stevenson LW, Thibault B, Waldo AL, Wyse DG, Roy D. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;55:1796-1802.
45. Weinfeld MS, Drazner MH, Stevenson WG, Stevenson LW. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. J Heart Lung Transplant. 2000;19:638-643. (Pubitemid 30621675)
46. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237. (Pubitemid 40110811)
47. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ; Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857-865. (Pubitemid 29427047)
48. Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678.
49. Kober L, Torp-Pedersen C, McMurray JJV, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687. (Pubitemid 351860860)
50. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedarone in High-Risk Permanent Atrial Fibrillation. N Engl J Med. 2011;365:2268-2276.
51. Chen MS, Marrouche NF, Khayakin Y, Gillinov M, Wazni O, Martin DO, Rossillo A, Verma A, Cummings J, Erciyes D, Saad E, Bhargava M, Bash D, Schweikert R, Burkhardt D, Williams-Andrews M, Perez-Lugones A, Abdul-Karim A, Saliba W, Natale A. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J Am Coll Cardiol. 2004;43:1004-1009. (Pubitemid 38352980)
52. Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquie JL, Scavee C, Bordachar P, Clementy J, Haissaguerre M. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351:2373-2383.
53. Tondo C, Mantica M, Russo G, Avella A, De Luca L, Pappalardo A, Fagundes RL, Picchio E, Laurenzi F, Piazza V, Bisceglia I. Pulmonary vein vestibule ablation for the control of atrial fibrillation in patients with impaired left ventricular function. Pacing Clin Electrophysiol. 2006;29: 962-970. (Pubitemid 44392884)
54. Gentlesk PJ, Sauer WH, Gerstenfeld EP, Lin D, Dixit S, Zado E, Callans D, Marchlinski FE. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007; 18:9-14. (Pubitemid 44952735)
55. Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweiker R, Saliba W, Wang P, Al-Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla V, Bonso A, Casella M, Raviele A, Haissaguerre M, Natale A; for the PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359:1778-1785.
56. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Card. 2008;5:159-168.
57. Nishimura RA, Holmes DR Jr. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 2004;350:1320-7. (Pubitemid 38375367)
58. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation. 1995;92:785-789.
59. Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 1999;33:1590-1595.
60. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517-2524. (Pubitemid 33107372)
61. Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, Matsumura Y, Yabe T, Takata J, Doi YL. Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy: results from Kochi RYOMA Study. Circ J. 2009;73:1599-1605.
62. Gil ML, Arribas F, Cosio FG. Ventricular fibrillation induced by rapid atrial rates in patients with hypertrophic cardiomyopathy. Europace. 2000;2:327-332.
63. Favale S, Pappone C, Nacci F, Fino F, Resta F, Dicandia CD. Sudden death due to atrial fibrillation in hypertrophic cardiomyopathy: a predictable event in a young patient. Pacing Clin Electrophysiol. 2003;26: 637-639. (Pubitemid 36403347)
64. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH III, Spirito P, Ten Cate FJ, Wigle D, Vogel RA, Abrams J, Bates ER, Brodie BR, Danias PG, Gregoratos G, Hlatky MA, Hochman JS, Kaul S, Lichtenberg RC, Lindner JR, O'Rourke RA, Pohost GM, Schofield RS, Tracy CM, Winters WL Jr, Klein WW, Priori SG, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Deckers J, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42: 1687-1713. (Pubitemid 37383745)
65. Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008;19:1118-1126.
66. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S. Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251-8. (Pubitemid 40523146)
67. Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha Y-M, Rea RF, Shen W-K, Powell BD, Ommen SR, Monahan KH, Haroldson JM, Packer DL. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008;19: 1009-1014.
68. Di Donna P, Olivotto I, Delcre SDL, Caponi D, Scaglione M, Nault I, Montefusco A, Girolami F, Cecchi F, Haissaguerre M, Gaita F. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace. 2010; 12:347-355.
69. Liu X, Ouyang F, Mavrakis H, Ma C, Dong J, Ernst S, Bansch D, Antz M, Kuck K-H. Complete pulmonary vein isolation guided by threedimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Europace. 2005;7:421-427. (Pubitemid 41130646)
70. Diker E, Aydogdu S, Ozdemir M, Kural T, Polat K, Cehreli S, Erdogan A, Goksel S. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. Am J Cardiol. 1996;77:96-98. (Pubitemid 26011643)
71. Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without surgery: ten-and twenty-year perspectives. Ann Intern Med. 1960;52:741-749.
72. Olesen KH. The natural history of 271 patients with mitral stenosis under medical treatment. Br Heart J. 1962;24:349-357.
73. Grigioni F, Avierinos JF, Ling LH, Scott CG, Bailey KR, Tajik AJ, Frye RL, Enriquez-Sarano M. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol. 2002;40:84-92. (Pubitemid 34701381)
74. Coulshed N, Epstein EJ, McKendrick CS, Galloway RW, Walker E. Systemic embolism in mitral valve disease. Br Heart J. 1970;32: 26-34.
75. Abernathy WS, Willis PW III. Thromboembolic complications of rheumatic heart disease. Cardiovasc Clin. 1973;5:131-75.
76. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol. 2006;48: e1-e148.
77. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341:142-147. (Pubitemid 29325741)
78. Handa N, Schaff HV, Orszulak TA, Morris JJ. Outcome of valve repair and the Cox Maze procedure for mitral regurgitation and associated atrial fibrillation. J Thorac Cardiovasc Surg. 1999;118: 628-635. (Pubitemid 29474788)
79. Schaff HV, Dearani JA, Daly RC, Orszulak TA, Danielson GK. Cox-Maze procedure for atrial fibrillation: Mayo Clinic experience. Semin Thorac Cardiovasc Surg. 2000;12:30-37.
80. Kobayashi J, Sasako Y, Bando K, Niwaya K, Tagusari O, Nakajima H, Ishida M, Kitamura S. Eight-year experience of combined valve repair for mitral regurgitation and Maze procedure. J Heart Valve Dis. 2002;11: 165-171.
81. Abreu Filho CAC, Lisboa LA, Dallan LA. Effectiveness of the Maze procedure using cooled-tip radiofrequency ablation in patients with permanent atrial fibrillation and rheumatic mitral valve disease. Circulation. 2005;112:I20-I25. (Pubitemid 41266648)
82. Marelli AJ, Mackie AS, Ionesc-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007;115:163-172. (Pubitemid 46105714)
83. Bouchardy J, Therrien J, Pilote L, Ionescu-Ittu R, Martucci G, Bottega N, Marelli AJ. Atrial arrhythmias in adults with congenital heart disease. Circulation. 2009;120:1679-1686.
84. Triedman JK. Arrhythmias in adults with congenital heart disease. Heart. 2002;87:383-389. (Pubitemid 34270958)
85. Kirsh JA, Walsh EP, Triedman JK. Prevalence of and risk factors for atrial fibrillation and intra-atrial reentrant tachycardia among patients with congenital heart disease. Am J Cardiol. 2002;90:338-340. (Pubitemid 34804577)
86. Trojnarksa O, Grajek S, Kramer L, Gwizdalla A. Risk factors of supraventricular arrhythmia in adults with congenital heart disease. Cardiol J. 2009;16:218-226.
87. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. J Am Coll Cardiol. 2008;52:e143-e263.
88. Miyazaki A, Ohuchi H, Kurosaki K, Kamakura S, Yagihara T, Yamada O. Efficacy and safety of sotalol for refractory tachyarrhythmias in congenital heart disease. Circ J. 2008;72:1998-2003.
89. Wells R, Khairy P, Harris L, Anderson CC, Balaji S. Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study. Pacing Clin Electrophysiol. 2009;32:1313-1318.
90. Malhotra R, Mason P. Lamin A/C deficiency as a cause of familial dilated cardiomyopathy. Curr Opin Cardiol. 2009;24:203-208
91. Gollob MH, Green MS, Tang ASL, Roberts R. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol. 2002;17:229-234. (Pubitemid 34553626)
92. Sabeh MK, MacRae CA. The genetics of atrial fibrillation. Curr Opin Cardiol. 2010;25:1-6.
93. van Berlo JH, deVoogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, Yaou RB, Duboc D, Rossenbacker T, Heidbuchel H, de Visser M, Crijns HJGM, Pinto YG. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med. 2005;83:79-83. (Pubitemid 40169500)
94. van Tintelen JP, Hofstra RMW, Katerberg H, Rossenbacker T, Wiesfeld ACP, du Marchie Sarvaas GJ, Wilde AAM, van Langen IM, Nannenberg EA, van der Kooi AJ, Kraak M, van Gelder IC, van Veldhuisen DJ, Vos Y, van den Berg MP. High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J. 2007;154:1130-1139. (Pubitemid 350116040)
95. Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H, Schulze-Bahr E, Breithardt G, Haverkamp W. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol. 2003;14:1027-1033. (Pubitemid 37412078)
96. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm. 2008;5:704-709.
97. El Yaman M, Perry J, Makielski JC, Ackerman MJ. Suppression of atrial fibrillation and mexiletine pharmacotherapy in a young woman with type 1 long QT syndrome. Heart Rhythm. 2008;5:472-474.
98. Schimpf R, Wolpert C, Gaita F, Giustetto C, Borggrefe M. Short QT syndrome. Cardiovasc Res. 2005;67:357-366. (Pubitemid 41019545)
99. Patel U, Pavri BB. Short QT syndrome: a review. Cardiol Rev. 2009; 17:300-303.
100. Babai Bigi MA, Aslani A, Shahrzad S. Clinical predictors of atrial fibrillation in Brugada syndrome. Europace. 2007;9:947-950 (Pubitemid 351773299)